STRATA Skin Sciences Stock (NASDAQ:SSKN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.12

52W Range

$0.11 - $3.86

50D Avg

$0.16

200D Avg

$1.02

Market Cap

$609.18K

Avg Vol (3M)

$22.56K

Beta

-0.08

Div Yield

-

SSKN Company Profile


STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment. With a substantial global footprint, STRATA Skin Sciences distributes its solutions across the United States, Europe, the Middle East, Asia, Australia, South Africa, and both Central and South America. Its notable product portfolio includes the XTRAC and Pharos excimer laser systems, VTRAC lamp systems, and TheraClear treatment solutions. These technologies are instrumental in addressing common skin ailments such as psoriasis, vitiligo, and acne, among others. Domestically, the company engages directly with physicians for product distribution, while leveraging a network of international distributors to reach markets beyond the U.S. Established in 1989 and headquartered in Horsham, Pennsylvania, the company adopted its current name, STRATA Skin Sciences, Inc., in January 2016, having previously operated as MELA Sciences, Inc.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

106

IPO Date

Nov 03, 2005

Website

SSKN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Dermatology Recurring Procedures$21.17M$21.53M$23.02M
Dermatology Procedures Equipment$12.39M$11.83M$13.14M

Fiscal year ends in Dec 25 | Currency in USD

SSKN Financial Summary


Dec 25Dec 24Dec 23
Revenue$30.70M$33.56M$33.36M
Operating Income$-4.70M$-9.26M$-8.60M
Net Income$-6.26M$-10.09M$-10.83M
EBITDA$-4.70M$-2.84M$-3.38M
Basic EPS$-1.35$-0.26$-0.31
Diluted EPS$-1.35$-0.26$-0.31

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q3 25Nov 13, 25 | 4:30 PM
Q2 25Aug 13, 25 | 4:30 PM
Q1 25May 14, 25 | 4:30 PM

Peer Comparison


TickerCompany
MHUAMeihua International Medical Technologies Co., Ltd.
ADXNAddex Therapeutics Ltd
PAVMPAVmed Inc.
NRSNNeuroSense Therapeutics Ltd.
BMRABiomerica, Inc.
ADILAdial Pharmaceuticals, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
IINNInspira Technologies Oxy B.H.N. Ltd.
HSCSHeartSciences Inc.